Twist Bioscience (STU:0ME) Notes Receivable: €0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:0ME Twist Bioscience Corp STU:0ME
70 GF Score
Price €94.86
GF Value €45.37
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Twist Bioscience Notes Receivable?

Twist Bioscience STU:0ME +3.56% 70 Notes Receivable is €0.0 Mil as of Mar. 2026. GuruFocus rates STU:0ME with a GF Score™ of 70/100 and a GF Value™ of €45.37 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Twist Bioscience's Notes Receivable for the quarter that ended in Mar. 2026 was €0.0 Mil.

Twist Bioscience Notes Receivable Related Terms

Twist Bioscience Notes Receivable Historical Data

* Premium members only.

The historical data trend for Twist Bioscience's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Twist Bioscience Notes Receivable Chart

Twist Bioscience Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Twist Bioscience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:0ME
70GF Score
Twist Bioscience Corp STU:0ME
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Twist Bioscience Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.0 Mil mean?
Twist Bioscience (STU:0ME) has a Notes Receivable of €0.0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Twist Bioscience and its competitors.
Is Twist Bioscience's Notes Receivable too high?
Twist Bioscience's current Notes Receivable is €0.0 Mil. Overall, Twist Bioscience has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Twist Bioscience's Notes Receivable compare to BLLN and SHC?
Twist Bioscience's Notes Receivable of €0.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Diagnostics & Research company?
A good Notes Receivable depends on the Medical Diagnostics & Research industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Twist Bioscience and its competitors. Twist Bioscience's current Notes Receivable is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Twist Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Twist Bioscience (STU:0ME) is currently considered Significantly Overvalued. The stock's GF Value™ is €45.37, compared to a current price of €94.86 — trading 109.1% above its estimated fair value. The current Notes Receivable is €0.0 Mil. Twist Bioscience's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Twist Bioscience (STU:0ME), the current Notes Receivable is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Twist Bioscience (STU:0ME) Overvalued in 2026?

Based on GuruFocus' analysis, Twist Bioscience stock appears to be overvalued. The current stock price of €94.86 is trading 109.1% above its estimated GF Value™ of €45.37. GuruFocus considers Twist Bioscience to be Significantly Overvalued.

Key valuation signals for STU:0ME:

  • Notes Receivable: €0.0 Mil
  • GF Value™: €45.37 vs. price of €94.86 (109.1% above fair value)
  • GF Score™: 70/100 with 5 warning signs

No single metric tells the full story. See the STU:0ME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Twist Bioscience Business Description

Other Exchanges TWST:USA1TWST:Italy
Address 681 Gateway Boulevard, South San Francisco, CA, USA, 94080
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
70GF Score

Get the complete analysis for STU:0ME

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€94.86
Price
€45.37
GF Value